http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013039411-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be3e8fc83ec197446fc2053b1dbcfe72 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_73ea15696a191d4f5555fb94a08c0f1b http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_22d3c178abfb2673aec6f92c80c3b074 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc7fa5cc95fc560137f570dc5a2ac906 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e77fe6d1d93f1aeffa1009446386c843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_866de96f8c756bdaa1e468a2785deb6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dcd55ab016bd4f5d2302b8602972ed43 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54cf21328639716856d474a8aec64934 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-225 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L26-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L24-10 |
| filingDate | 2012-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0a3b588fefde84b737b33c1396d33ce7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0c695193697f0a5259e7e69a346c18de http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8336942c778228e321f5d1f915706234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_071732129d797d739cbff84b10f9f89a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b784c0173bae86ea1031fd06350e0464 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2c94838f4e8809e73cda35594254dcf http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_882e08921154ed13cb3ea031daca415a |
| publicationDate | 2013-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2013039411-A1 |
| titleOfInvention | Autologous and allogenic fibrin carrier, method of obtaining thereof and use of a fibrin carrier for transplantation of cells, particularly human cells |
| abstract | An autologous and allogenic fibrin carrier characterized in that it is a gel-like mixture of fibrinogen and platelet-rich plasma combined at a ratio 0.1-2 to 0.1 -2, favorably 1 : 1 of volume share, and a calcium chloride in a 0.1-99% solution, favorably a 10% solution at a ratio 0.1-2 to 0.1-2, favorably 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. A method of obtaining an autologous fibrin carrier comprising blood collection, separation of blood plasma from blood cells, freezing and thawing of blood plasma, characterized in that the blood donation collected from the blood donor is separated from the concentrate of blood cells, i.e. erythrocytes, leukocytes being removed, said separation having the form of centrifugation at + 20 to + 24°C for 5 to 15 minutes, with centrifugation force of 700 to 2000 x g; afterwards plasma is pushed through to an empty satellite container, wherein centrifugation takes place at + 20°C to +24°C for 5-15 minutes at a centrifugation force of 2100 to 5000 x g to separate platelet-rich plasma, which is stored in bags, favorably breathable swinging bags for maximum 7 days and favorably 3 days. The remaining platelet-poor plasma is used for preparation of fibrinogen in cryoprecipitate, by freezing blood plasma twice to the temperature of -30°C to -90°C and thawing blood plasma at about + 4°C, for example in a water bath, then it is centrifuged at about + 4°C for 5-20 minutes at centrifugation force of 1000 to 5000 x g, wherein supernatant is removed and resultant cryoprecipitate is mixed with platelet-rich plasma from the container, at a ratio from 0.1 -2 to 0.1 -2, favorably 1 : 1, and with a calcium compound solution, favorably a 10% calcium chloride solution at a favorable ratio 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. Use of an autologous fibrin carrier for obtaining a gel-like transplant, that is a carrier formed by mixing fibrinogen and platelet-rich plasma obtained from the recipient's blood, favorably of a single donation, or ready-made fibrinogen characterized by an adequate phenotype and platelet-rich plasma taken directly from the blood donation of the patient-recipient using the operating room's apparatus, wherein in the process of obtaining a carrier and prior to the addition of a 0.1%-99% calcium chloride solution at a ratio 0.1 -2 do 0.1-2, favorably 1 : 1 of volume share relative to the mixture of fibrinogen and platelet-rich plasma, from 5 thousand to 100 million recipient's cells or allogenic and xenogenic cells are added, cultured in a known way and processed on the transplantation's date by trypsinization, washing in a serum- containing medium and vitality assessment. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2017506657-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10806755-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2019196388-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2015221786-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2015238529-A1 |
| priorityDate | 2011-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.